Elsevier

Biochemical Pharmacology

Volume 80, Issue 8, 15 October 2010, Pages 1221-1229
Biochemical Pharmacology

Identification and characterization of a novel estrogenic ligand actinopolymorphol A

https://doi.org/10.1016/j.bcp.2010.06.030Get rights and content

Abstract

Xenoestrogenic compounds are abundant in the modern environment including phytoestrogens from plants, chemical by-products from industry, and secondary metabolites from microbes; all can profoundly affect human health. Consequently mechanism-based screens are urgently needed to improve the rate at which the xenoestrogens are discovered. Estrogen Receptor (ER) dimerization is required for target gene transcription. The three ER dimer pairs (ERα/α homodimers, ERβ/β homodimers, and ERα/β heterodimers) exhibit diverse physiological responses in response to ligand-dependent activation with ERα/α homodimers being pro-proliferative and ERβ/β homodimers being anti-proliferative. The biological role of the ERα/β heterodimer remains unclear. We previously developed a cell-based, bioluminescence resonance energy transfer (BRET) assay that can distinguish natural estrogenic compounds based on their abilities to activate the three diverse ER dimer pairs. Using BRET assays, we sought to identify novel xenoestrogens from soil bacteria that preferentially activate ERα/β heterodimer with hopes of shedding light on the biological function of this elusive dimer pair. Here we describe the application of BRET assays in high throughput screens of crude bacterial extracts not previously screened for ER modulatory function and originating from unique ecological niches. Here we report the discovery and biological evaluation of a new natural product, actinopolymorphol A (1), that preferentially induces ERα/β dimerization. Actinopolymorphol A represents the first representative of a new ER modulatory scaffold.

Introduction

The Estrogen Receptors (ERs) are hormone dependent transcription factors existing in two forms: ERα and ERβ. The binding of both endogenous (i.e. 17β-estradiol, also known as E2) and exogenous estrogenic ligands to these receptors induces conformational changes leading to dissociation from the Hsp90 molecular chaperone complex, subsequent receptor dimerization, interaction with coactivator proteins, and recognition of Estrogen Response Elements (EREs) in the promoter regions of target genes to activate target gene transcription. Transcriptional activity of ERs is strongly influenced by ligands at each step including (i) the binding of a given ligand for ERα vs. ERβ, (ii) the conformational changes induced upon ligand binding which influence dimer partner preference (i.e. ERα/α and ERβ/β homodimers, or ERα/β heterodimers), (iii) cofactor recruitment, and (iv) interaction with chromatin. The differential regulation of ERα and ERβ by endogenous and exogenous estrogenic compounds has extensive physiological implications, as transcriptional activation of ERα by these ligands is known to stimulate cellular proliferation, while transcriptional activation of ERβ inhibits cell growth [1], [2], [3], [4], [5], [6].

In addition to the genomic transcriptional activities of ERα and ERβ in estrogenic signaling, ERs can also be regulated by growth factors such as epidermal growth factor (EGF) and insulin-like growth factor (IGF) [7], [8], [9], [10]. The effects of many of these growth factor pathways are believed to reflect their abilities to change the phosphorylation state of ERs, as well as that of coregulators and other proteins with which ERs interact to modulate gene expression. Furthermore, in addition to the well-documented synergistic effects of estrogens and growth factors on gene transcription, estrogens also exert rapid membrane-initiated effects that are known to massively impact cell signaling and may also influence gene transcription in the nucleus. Membrane-bound ERs have been shown to mediate estrogenic effects in ER-negative cells via activation of the MAPK pathway [11]. These non-genomic mechanisms of estrogenic signaling should therefore be carefully considered as important mechanisms of global estrogen action.

The cellular functions of ERα and ERβ homodimers are well established. However, the biological role of the ERα/β heterodimer remains a topic for intense study and debate, due largely to the lack of tools to study ERα/β heterodimerization in a physiological context. The co-expression of ERα and ERβ results in a heterogeneous pool of homodimers and heterodimers, and thus the activity of heterodimers cannot be deciphered from that of either homodimer, although evidence strongly suggests that ERβ antagonizes the proliferative action of ERα via formation of growth-inhibitory heterodimers [1], [3], [4], [12], [13]. To elucidate the biological role of these heterodimers, we have developed novel bioluminescence resonance energy transfer (BRET) assays in order to study ERα/β heterodimerization in a cell-based, physiological environment in real time [14]. We have used these assays to study the basic intermolecular mechanism of ERα/β heterodimerization. Another important application of the BRET assay involves the identification of selective ERα/β heterodimer-inducing small molecules. Of particular significance here is the application of the BRET assay to identify new natural products able to activate ERα/β heterodimerization.

Exogenous estrogenic ligands are ubiquitous in the natural environment and include xenoestrogenic industrial by-products and phytoestrogens such as genistein, a principle constituent of soy. Metabolites of xenoestrogenic and phytoestrogenic compounds have been demonstrated to be produced by several bacterial strains including those present in the intestinal flora [15], [16], [17], [18], [19], [20] and soil bacteria [21], [22]. For example, bisphenol A (BPA) can be metabolized by many organisms ranging from microorganisms to animals, and these transformations represent an important pathway for its detoxification [23]. Other studies have shown that many natural products produced by bacteria serve as xenoestrogens [24], [25]. Screening of such compounds for their ability to selectively activate ER homodimers and heterodimers is important in order to determine the physiological effects of these environmental ligands as they may act through pro-proliferative ERα/α homodimers or anti-proliferative ERβ/β heterodimers. Moreover, the identification of such compounds represents an important undertaking as compounds displaying selective ER activation may serve as scaffolds which may be used for the development of novel therapeutics or biochemical tools. Inspired by the realization that the chemical structures of natural products remain either the source of, or the basis for, the majority of drug discovery and synthesis [26], this study sought to identify new natural products able to induce selective ER heterodimer formation leading to subsequent transcriptional activity with the rationale that these structures may be useful as a basis for chemical synthesis of therapeutically-useful ER dimer-selective ligands. Natural products of interest were produced by actinomycetes of terrestrial origin.

The application of our novel ER dimer-specific BRET assay [14], [27] for high throughput screening (HTS) of a microbial library of crude extracts resulted in the identification of actinopolymorphol A from the actinomycete Actinopolymorpha rutilus whose structure has not previously been reported or characterized as an ER ligand. This discovery was enabled by the novelty of the BRET assay with its rapid in-cell format which circumvents the need for tissue-culture grade crude extracts and serves as an excellent assay for activity-guided chemical fractionation of crude extracts containing an assortment of natural products.

Section snippets

High throughput screening BRET of the UWCCC SMSF Discovery Library

HTS BRET was performed at the University of Wisconsin Small Molecule Screening Facility. ERα/α homodimerization was examined using ERα-RLuc and ERα-YFP, ERβ/β homodimerization was examined using RLuc-ERβ and YFP-ERβ, and ERα/β heterodimerization was examined using ERα-RLuc and YFP-ERβ using the optimized conditions described previously [14]. Cells were transfected with these fusion proteins (0.73 μg RLuc fusion + 2.8 μg YFP fusion) in batches on 10 cm plates to reduce well-to-well variation in

High throughput BRET screening of the University of Wisconsin Discovery Library (WDL)

In order to identify ligands capable of differentially inducing ERα/α and ERβ/β homodimerization and ERα/β heterodimerization, a BRET assay was developed and optimized [14]. Distinct from the existing ER reporter assay, the BRET assay is exquisitely sensitive and allows the formation of different dimer types to be detected independently, including ERα/α, ERβ/β, and ERα/β dimers. This is especially important in the case of the ERα/β heterodimer, as the co-expression of ERα and ERβ allows the

Discussion

It is well established that phytochemicals serve as recruitment signals resulting in the symbiotic activation of plant growth signals by soil bacteria, and that the presence of endocrine disrupting compounds (EDCs) contained in pesticides and other industrial by-products can disrupt this process [38], [39], [40]. The direct production of xenoestrogenic compounds by soil bacteria is not as well established and therefore represents an opportunity for discovery of new chemical scaffolds with

Acknowledgements

We thank Erin Shanle for proofreading the manuscript and the Analytical Instrumentation Center of the School of Pharmacy, UW-Madison for support in obtaining MS and NMR data. This work is supported by NIH Grants R01CA125387 and R03MH089442 to W.X., T32 CA009135 to E.P. and CA113297 to B.S.

References (41)

  • E.C. Chang et al.

    Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells

    Endocrinology

    (2006)
  • L.A. Helguero et al.

    Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11

    Oncogene

    (2005)
  • K. Pettersson et al.

    Estrogen receptor beta acts as a dominant regulator of estrogen signaling

    Oncogene

    (2000)
  • B.S. Shoker et al.

    Oestrogen receptor expression in the normal and pre-cancerous breast

    J Pathol

    (1999)
  • S. Kato et al.

    Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

    Science

    (1995)
  • S.M. Aronica et al.

    Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I

    Mol Endocrinol

    (1993)
  • D.M. Ignar-Trowbridge et al.

    Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor

    Proc Natl Acad Sci USA

    (1992)
  • G. Bunone et al.

    Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation

    EMBO J

    (1996)
  • E.J. Filardo et al.

    Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF

    Mol Endocrinol

    (2000)
  • D.G. Monroe et al.

    Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells

    Mol Endocrinol

    (2005)
  • Cited by (28)

    • Activation of steroid hormone receptors: Shed light on the in silico evaluation of endocrine disrupting chemicals

      2018, Science of the Total Environment
      Citation Excerpt :

      However, it should be noted that dimerization here refers to the dimerization mediated by the LBDs of SHRs, and dimerization in general can be mediated by DBDs, NTDs and the hinges of SHRs. Dimerization is influenced by the binding of chemicals to the SHRs (Powell et al., 2010). Because of its importance in DNA binding and its consequent regulation of transcription, SHR dimerization is a characteristic feature of EDC screens (Shanle and Xu, 2011).

    • Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review

      2017, Bioorganic Chemistry
      Citation Excerpt :

      Clinical studies focusing on the use of therapeutic agents that prevent the synthesis and action of estrogens (ER antagonists) are known to be very successful in the treatment of breast cancer. Development of ER antagonists as a new approach for the treatment of postmenopausal women with hormone-dependent breast tumors has been carried out [83]. The high levels of estrogen, as a result of it in situ synthesis, are associated with the growth of tumors in endocrine-dependent tissues.

    • Estrogenic effects of fusarielins in human breast cancer cell lines

      2012, Toxicology Letters
      Citation Excerpt :

      Fusarin C, another bioactive compound produced by F. graminearum, was recently shown to be an estrogenic agonist although it is structurally different from known estrogenic compounds (Sondergaard et al., 2011). Actinopolymorphol A isolated from an actinomycete is another example of an estrogenic ligand which is not structurally related to estrogen (Powell et al., 2010). These reports indicate that it is difficult to predict the estrogenic effects solely based on compound structure.

    • Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands

      2011, Biochemical Pharmacology
      Citation Excerpt :

      Competitive ligand binding assays provide insight into binding affinities and are useful for high throughput small molecule screening [37], but they are limited because ligands can act as agonists or antagonists and binding affinity does not often reflect transcriptional potency. Subtype selective ligands have been identified using BRET assays that measure receptor dimerization [38], but dimerization assays cannot differentiate between agonists or antagonists [39]. Agonists can be characterized using MCF7 cell proliferation assays, which are highly sensitive and provide a biologically relevant endpoint in the context of estrogen-sensitive cells [40].

    View all citing articles on Scopus
    View full text